Prelude Therapeutics spent the past year cutting a stalled chromatin program and concentrating the remaining science on two first-in-human bets that the market can actually underwrite. The company paused SMARCA2 development in late 2025, handed Incyte an exclusive option on the mutant-selective JAK2 program, and used a spring underwritten offering to refill the balance sheet. That sequence turned a cash-constrained discovery shop into a funded clinical-stage name whose next stretch of work is about enrollment, not survival. The September investigational-new-drug clearance on the wholly owned KAT6A degrader removes the last paper hurdle before that second program can enter the clinic.
The tension is that almost none of the new operating story is yet visible in human data. Collaboration revenue in the second quarter is the accounting echo of the Incyte option, not a commercial franchise. Research spending fell because the SMARCA2 trials stopped and headcount came down, not because a product is becoming cheaper to make. Cash of $155 million at mid-year, plus management's claim that the pile lasts into early 2028, buys time. It does not buy proof. The equity therefore trades as a sum of an Incyte call option, an unencumbered breast-cancer degrader, and a discovery conjugate effort, minus the dilution already taken to keep the lights on.
Second-quarter revenue of just under $6 million sat against a net loss of $14 million, a much smaller hole than a year earlier. The print confirms the reset is showing up in the income statement. The open question is whether Incyte exercises, whether the KAT6A study actually enrolls on the stated fourth-quarter timetable, and whether first-in-human safety on either asset is clean enough to keep the option and the wholly owned program both alive.